Mikkel Christensen

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi Medication review in hospitalised patients to reduce morbidity and mortality
    Mikkel Christensen
    Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark
    Cochrane Database Syst Rev 2:CD008986. 2013
  2. ncbi GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
    Maria J Jespersen
    University of Copenhagen, Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark
    Expert Opin Drug Metab Toxicol 9:17-29. 2013
  3. ncbi Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans
    Mikkel Christensen
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, Copenhagen, Denmark
    Diabetes 60:3103-9. 2011
  4. ncbi Lixisenatide for type 2 diabetes mellitus
    Mikkel Christensen
    University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Hellerup, Denmark
    Expert Opin Investig Drugs 20:549-57. 2011
  5. ncbi [Colonic malacoplakia treated with sulfamethizole and trimethoprim]
    Mikkel Christensen
    Medicinsk afdeling, Amager Hospital, Denmark
    Ugeskr Laeger 173:509-10. 2011
  6. ncbi Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes
    Mikkel Christensen
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
    Regul Pept 163:96-101. 2010
  7. ncbi Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
    Tina Vilsbøll
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DK 2900 Hellerup, Denmark
    BMJ 344:d7771. 2012
  8. ncbi The alpha-cell as target for type 2 diabetes therapy
    Mikkel Christensen
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Rev Diabet Stud 8:369-81. 2011
  9. ncbi Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes
    Espen Jimenez-Solem
    University of Copenhagen, Gentofte Hospital, Department of Internal Medicine F, Niels Andersens Vej 65, 2900 Hellerup, Denmark
    Curr Opin Mol Ther 12:790-7. 2010
  10. ncbi Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?
    Mikkel Christensen
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
    Curr Diab Rep 10:124-32. 2010

Collaborators

Detail Information

Publications12

  1. ncbi Medication review in hospitalised patients to reduce morbidity and mortality
    Mikkel Christensen
    Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark
    Cochrane Database Syst Rev 2:CD008986. 2013
    ..Medication review performed in adult hospitalised patients may lead to better patient outcomes...
  2. ncbi GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
    Maria J Jespersen
    University of Copenhagen, Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark
    Expert Opin Drug Metab Toxicol 9:17-29. 2013
    ..The future place of these agents will depend on the added safety and efficacy data in the several ongoing cardiovascular outcome trials...
  3. ncbi Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans
    Mikkel Christensen
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, Copenhagen, Denmark
    Diabetes 60:3103-9. 2011
    ..To evaluate the glucose dependency of glucose-dependent insulinotropic polypeptide (GIP) effects on insulin and glucagon release in 10 healthy male subjects ([means ± SEM] aged 23 ± 1 years, BMI 23 ± 1 kg/m(2), and HbA(1c) 5.5 ± 0.1%)...
  4. ncbi Lixisenatide for type 2 diabetes mellitus
    Mikkel Christensen
    University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Hellerup, Denmark
    Expert Opin Investig Drugs 20:549-57. 2011
    ....
  5. ncbi [Colonic malacoplakia treated with sulfamethizole and trimethoprim]
    Mikkel Christensen
    Medicinsk afdeling, Amager Hospital, Denmark
    Ugeskr Laeger 173:509-10. 2011
    ..The condition resolved during three months of antibiotic treatment with sulfamethizole and trimethoprim...
  6. ncbi Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes
    Mikkel Christensen
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
    Regul Pept 163:96-101. 2010
    ..In conclusion, GLP-2, but not GIP, was found to stimulate the release of glucagon in patients with T1DM, suggesting a role for GLP-2 in the postprandial hyperglucagonaemia characterising individuals with T1DM...
  7. ncbi Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
    Tina Vilsbøll
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DK 2900 Hellerup, Denmark
    BMJ 344:d7771. 2012
    ..To determine whether treatment with agonists of glucagon-like peptide-1 receptor (GLP-1R) result in weight loss in overweight or obese patients with or without type 2 diabetes mellitus...
  8. ncbi The alpha-cell as target for type 2 diabetes therapy
    Mikkel Christensen
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Rev Diabet Stud 8:369-81. 2011
    ..At present, available pharmacological agents based on the glucose-dependent glucagonostatic effects of GLP-1 represent the most favorable way to apply constraints to the alpha-cell in type 2 diabetes...
  9. ncbi Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes
    Espen Jimenez-Solem
    University of Copenhagen, Gentofte Hospital, Department of Internal Medicine F, Niels Andersens Vej 65, 2900 Hellerup, Denmark
    Curr Opin Mol Ther 12:790-7. 2010
    ..If dulaglutide possesses similar efficacy to other GLP-1 analogs, the once-weekly treatment will most likely be welcomed by patients with T2DM...
  10. ncbi Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?
    Mikkel Christensen
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
    Curr Diab Rep 10:124-32. 2010
    ....
  11. ncbi Therapy for obesity based on gastrointestinal hormones
    Jonatan I Bagger
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Rev Diabet Stud 8:339-47. 2011
    ..This review discusses the effects of the incretin-based therapies in obesity, and provides an overview of intestinal peptides with promising effects as potential new treatments for obesity...
  12. ncbi Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus
    Mikkel Christensen
    Amager Hospital, Department of Internal Medicine, University of Copenhagen, Denmark
    IDrugs 12:503-13. 2009
    ....